Common Name(s): Lumixyl,decapeptide-12
CAS Number: N/a
DESCRIPTION
What It Does: Inhibits tyrosinase activity via competitive inhibition for skin brightening with minimal irritation.
Why It's Used: Peptide brightening for sensitive skin where acid-based brighteners or classic tyrosinase inhibitors cause unacceptable irritation.
How It Works: Tyrosinase competitive inhibitor blocking melanin synthesis upstream. peptide structure provides high selectivity for tyrosinase with minimal off-target effects โ superior specificity vs small-molecule inhibitors.
Typically Found In: Brightening serums,sensitive skin brightening,premium hyperpigmentation treatments
TECHNICAL DETAILS
Primary Category: Active ingredient โ brightening peptide
Secondary Functions: Tyrosinase inhibition,sensitive-skin brightening
Application Areas:
Facial Skincare
Body Care
Hair Care
Beard Care
Color Cosmetics (Makeup)
Dietary/Oral Supplements
Typical Concentration Range: 0.01%โ0.1%
SOURCING & ETHICS
Vegan Status: Conditional - supplier confirmation required
Halal Status: Unverified - supplier confirmation required
Source Notes: Spps synthesis. academic origin from stanford dermatology research. [audit 2026-07-29 rev2: the record's own source_notes does not assert a non-animal origin, or instructs the reader to verify with the supplier; "yes" asserts knowledge the record does not hold. determination requires shariah-panel sign-off.]
SKIN COMPATIBILITY
Irritancy Rating: 1/5 โ very low
Comedogenicity Rating: 0/5 โ non-comedogenic
Sensitivity Concerns: Non-irritating; well-tolerated.
Safe for Sensitive Skin: Yes
SAFETY & COMPATIBILITY
Safety Profile: Excellent safety profile. use with spf for maximum efficacy. ewg score: 1.
Works Well With: Niacinamide,vitamin c,alpha-arbutin,tranexamic acid,spf
Avoid Combining With: No significant incompatibilities
SCIENTIFIC NOTE
Peptide tyrosinase inhibitors provide superior enzyme selectivity vs small-molecule inhibitors (kojic acid, arbutin) because they can occupy the enzyme active site with greater specificity, reducing off-target interactions and the sensitization concerns associated with small-molecule inhibitors.
Last Verified: 2026-03-12
Primary Sources: Cosing database,kimura et al. peptide brightening research